Cytokinetics' heart failure drug improves exercise capacity, sending shares soaring in...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 27, 2023 at 11:22: PM
via Cytokinetics’ Christmas wish has come true. Cardiomyopathy treatment aficamten has improved exercise capacity in a pivotal phase 3 trial, sending the biotech’s shares soaring by more than 50% in pre-market trading Wednesday.

article source
 

<



Similar threads

cafead
FDA advisers nix Cytokinetics&#039; heart failure med, rejecting argument for subgroup use
Replies
0
Views
259
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Investors say &#039;no bueno&#039; as Cytokinetics stymies M&amp;A prospects with complex...
Replies
0
Views
96
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cytokinetics shows hand in high stakes rivalry with BMS&#039; Camzyos
Replies
0
Views
173
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics&#039;...
Replies
0
Views
294
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cytokinetics&#039; comeback attempt with second-gen drug is slammed by a PhII failure in ALS
Replies
0
Views
224
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote